In the first installment of our series on trials in India, we look at the upsides, downsides and numbers. more...

BBK Worldwide discusses how to find patients for the most problematic trials. more...

In a sobering but illuminating first day, the 2009 Clinical Trials Congress surveyed the industry and considered a new idea: economics. more...

iGuard expected to draw 60,000 members in a year. Instead, it attracted 750,000. The coming shift in strategy—and genomics. more...

At the RAPS conference, FDA and Duke discuss the audacious Clinical Trial Transformation Initiative. more...

Things are still going well at CRN, which relies on a network of nurses that can visit patients at home. more...

The patient-recruitment firm talks about using the right data and spending what is necessary. more...

The Pittsburgh diary company invivodata has been dredging up facts about patient-reported outcomes. more...

Four clinical organizations in Massachusetts have come together to help regions that want to get more of the global medical research pie. more...

The tribulations of filling your trial in the era of global studies. A report from the 2008 DIA conference. more...

What’s different this year. Random thoughts on our personal nemesis, paper, and the alternative. more...

Joseph Camardo spoke at the Post-Approval Summit at Harvard, and was wicked smart. Even so, what he didn’t say perturbed us. more...

Consultant Ron Waife of Waife & Associates discusses what eclinical means and why it matters. more...

The conference industry should borrow an idea from the medical journals, our guest author says. more...

Lilly discusses how data management is changing in the era of electronic data capture. more...

Moving work to India is not just about cost, says Bristol Myers. It’s about performance and quality too. more...